Chronic News and Research

RSS

YM BioSciences receives approval to expand enrolment in Phase I/II clinical trial of CYT387

YM BioSciences Inc., announced that it has received ethics board approval to expand enrolment in its Phase I/II clinical trial of CYT387 at Mayo Clinic in patients with myelofibrosis, a chronic debilitating condition, where patient's bone marrow is replaced by scar tissue.

31 Mar 2010

Novo Nordisk BlueSheet launched to provide information on diabetes and chronic disease

Novo Nordisk, a global healthcare company and leader in diabetes care, today announced the launch of the Novo Nordisk BlueSheet, a resource for information on diabetes and chronic disease, highlighting key issues in diabetes prevention, detection, treatment and care.

30 Mar 2010

Two Phase I studies of Stedivaze demonstrate safety in patients with asthma and COPD

Clinical Data, Inc., today announced results from two Phase I studies of Stedivaze™ (apadenoson), which demonstrated that Stedivaze was safe and well tolerated in patients with asthma and chronic obstructive pulmonary disease (COPD). Stedivaze is a potent and highly selective agonist of the adenosine A2A receptor subtype in development as a pharmacologic stress agent for myocardial perfusion imaging (MPI).

30 Mar 2010

Savient Pharmaceuticals' resubmission of BLA for KRYSTEXXA accepted for FDA review

Savient Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has acknowledged receipt of and accepted for review the March 15, 2010 resubmission of the Biologics License Application for KRYSTEXXA™ (pegloticase), a treatment for chronic gout in patients refractory to conventional therapy.

30 Mar 2010

Mood altering effects of Phenytoin

Phenytoin is a well known antiepileptic agent widely used throughout the world. Recent clinical studies in patients with bipolar disorder have suggested that, as for other anticonvulsant drugs commonly used in the treatment of bipolar patients including valproate and carbamazepine, phenytoin may have mood-stabilizing effects in addition to its well-known anticonvulsant properties.

30 Mar 2010

Healthy hearts: Interventions needed to keep people exercising following cardiac rehabilitation programs

Researchers from the Frances Payne Bolton School of Nursing at Case Western Reserve University found that one year after 248 individuals completed a 12-week cardiac rehabilitation program following a heart attack, bypass surgery or angioplasty, only 37% exercised three times a week to keep their hearts healthy.

30 Mar 2010

National Donate Life Month: Facts surrounding dire need for organ donations

With Thursday, April 1, 2010, marking the start of "National Donate Life Month," Health Net, Inc. is working to increase awareness regarding the urgent need for organ donations - particularly among minority populations - and also to dispute some of the misperceptions surrounding organ donation.

30 Mar 2010

Preventive health care researchers meet to outline vision for evidence-based prevention in health care

Leading preventive health care researchers, physicians and executives assembled at U.S. Preventive Medicine® Friday to outline their vision for advancing evidence-based prevention in health care.

30 Mar 2010

Plaques in blood vessels may break by overproducing protein-digesting enzymes

University of Washington (UW) researchers have gathered evidence that dangerous plaques in blood vessels can rupture by overproducing protein-digesting enzymes. Plaques are fat-laden rough spots in the otherwise smooth walls of arteries. When a plaque ruptures, blood accumulates inside of it, a process known as plaque hemorrhage. The plaque enlarges and artery-blocking clots can form. If the flow of oxygen-rich blood is restricted, a heart attack, stroke, or damage to other organs can occur.

30 Mar 2010

Fecal incontinence: Sacral nerve stimulation along with Medtronic InterStim Therapy promising

Data published in the March issue of the Annals of Surgery show that investigational use of sacral nerve stimulation with Medtronic InterStim® Therapy reduces fecal incontinent episodes and increases quality of life in patients with the condition. The 120-patient, multi-center study - the largest trial of its kind in the world and the first such trial in North America - examined the efficacy of InterStim Therapy in patients with chronic fecal incontinence who had failed or were not candidates for more conservative treatments.

30 Mar 2010

New home health provisions proposed in Health Care Reform Bill to benefit older patients

New home health provisions proposed in the Health Care Reform Bill (H.R. 3590 Patient Protection and Affordable Care Act) will support the testing and implementation of in-home health care services for chronically ill elderly residents of Greater Philadelphia.

30 Mar 2010

CEO Roundtable on Cancer announces Gold Standard accreditation for Susan G. Komen for the Cure

Susan G. Komen for the Cure®, the world's largest breast cancer organization, has received CEO Cancer Gold Standard™ accreditation, recognizing the organization's commitment to reducing the risk of cancer for its employees and their families by promoting healthy lifestyle choices, by encouraging early detection through cancer screenings, and by ensuring access to quality treatment.

30 Mar 2010

Dicerna Pharmaceuticals, Ipsen announce collaboration in DsiRNA research and peptide engineering

Dicerna Pharmaceuticals, Inc., (Dicerna) a second generation RNA interference (RNAi) company, and Ipsen, a global biotechnology specialty care group, announced today that the two companies have entered into an exclusive research collaboration agreement to leverage their expertise in Dicer Substrate siRNA (DsiRNA) research and peptide engineering. The companies will develop novel conjugates of Dicerna's DsiRNA molecules and Ipsen's peptide targeting vectors in the therapeutic areas of oncology and endocrinology.

30 Mar 2010

LeAnn Rimes encourages psoriasis patients to take Make a Change Pledge

Grammy Award-winning multi-platinum recording artist and psoriasis patient LeAnn Rimes is calling for people with psoriasis to pledge to better manage their disease as part of the awareness campaign "Stop Hiding from Psoriasis." In partnership with the American Academy of Dermatology and National Psoriasis Foundation, LeAnn is encouraging people to take a stand against psoriasis by taking the Make a Change Pledge online at StopHiding.org.

30 Mar 2010

Researchers to study health literacy among Indigenous people living with cardiovascular disease

Researchers at St. Michael's Hospital in Toronto are part of an international team of researchers recently awarded a multi-million dollar grant for their work in cardiovascular disease among Indigenous people in Canada, Australia and New Zealand. The Canadian team will receive $742,000 in funding for its part of the project from the Canadian Institutes of Health Research and International Collaborative Indigenous Health Research Partnerships.

30 Mar 2010

FDA grants IDE approval for Urovalve's Surinate Bladder Management System

Urovalve, a medical device company focused on creating superior products for urinary flow and control, announced today that the U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval for the Company's Surinate® Bladder Management System, allowing Urovalve to conduct a clinical study for the Company's lead device in the United States.

29 Mar 2010

Positive results from Pearl Therapeutics' Phase 1 study of inhaled combination bronchodilator for COPD

Pearl Therapeutics Inc., a company developing clinically differentiated combination therapies for the treatment of highly prevalent chronic respiratory diseases, today announced positive results from a Phase 1 safety and pharmacokinetics study of PT003, its lead combination therapeutic for the treatment of chronic obstructive pulmonary disease (COPD). Based on these results, and previously announced positive results from Phase 2a studies of PT003's individual components, the company has advanced PT003 into a Phase 2b trial.

29 Mar 2010

Genta reports net loss of $11.7M for fourth-quarter 2009

Genta Incorporated today reported results for the quarter and year ended December 31, 2009. The Company also provided an overview of recent corporate highlights and anticipated milestones.

29 Mar 2010

High fructose corn syrup linked to skyrocketing rates of obesity

According to the Centers for Disease Control and Prevention, the rates of obesity in the United States have skyrocketed since the introduction of high fructose corn syrup in 1970. In that time, obesity rates have gone from 15 percent of the U.S. population to roughly one-third.

29 Mar 2010

StockPreacher.com announces investment report featuring ARCA biopharma

StockPreacher.com announces an investment report featuring ARCA biopharma Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

29 Mar 2010

Chronic News and Research

YM BioSciences receives approval to expand enrolment in Phase I/II clinical trial of CYT387

Novo Nordisk BlueSheet launched to provide information on diabetes and chronic disease

Two Phase I studies of Stedivaze demonstrate safety in patients with asthma and COPD

Savient Pharmaceuticals' resubmission of BLA for KRYSTEXXA accepted for FDA review

Mood altering effects of Phenytoin

Healthy hearts: Interventions needed to keep people exercising following cardiac rehabilitation programs

National Donate Life Month: Facts surrounding dire need for organ donations

Preventive health care researchers meet to outline vision for evidence-based prevention in health care

Plaques in blood vessels may break by overproducing protein-digesting enzymes

Fecal incontinence: Sacral nerve stimulation along with Medtronic InterStim Therapy promising

New home health provisions proposed in Health Care Reform Bill to benefit older patients

CEO Roundtable on Cancer announces Gold Standard accreditation for Susan G. Komen for the Cure

Dicerna Pharmaceuticals, Ipsen announce collaboration in DsiRNA research and peptide engineering

LeAnn Rimes encourages psoriasis patients to take Make a Change Pledge

Researchers to study health literacy among Indigenous people living with cardiovascular disease

FDA grants IDE approval for Urovalve's Surinate Bladder Management System

Positive results from Pearl Therapeutics' Phase 1 study of inhaled combination bronchodilator for COPD

Genta reports net loss of $11.7M for fourth-quarter 2009

High fructose corn syrup linked to skyrocketing rates of obesity

StockPreacher.com announces investment report featuring ARCA biopharma

Industry Focus eBook - Cell biology (5th edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News